Visit our Re-post guidelines
A paradigm-shifting study indicates that the standard of care for diabetics, including synthetic insulin and oral anti-diabetic drugs, increases morbidity and mortality from diabetes. Natural substances, on the other hand, have proven healing properties that if used, could mitigate the global diabetes epidemic.
A new study titled, "Glucose-lowering with exogenous insulin monotherapy in type 2 diabetes: dose association with all-cause mortality, cardiovascular events, and incident cancer," renews concern over the harms caused by synthetic insulin in type 2 diabetics previously highlighted in a 2013 study that found double the death rate in type 2 diabetics on insulin therapy.
Contrary to popular notions about the 'life saving' value of synthetic insulin -- a belief cleverly inculcated by Big pharma over the past three decades -- bioidentical-sounding insulin brands such as Humulin (1978) and Humolog (1996) are less like human insulin in form and function than pig pancreas-derived forms, which they displaced from the market soon after being introduced (you can no longer buy pig-derive insulin in the U.S.). Originally produced from genetically modified yeast, synthetic insulin's structure, and subsequent folding pattern (conformation) and function, radically diverge from the type of insulin our bodies produce naturally. For instance, one of the best-selling forms on the market today Lantus (insulin glargine [rDNA origin] injection), which is manufactured from Sanofi from GM engineered E. Coli, does not even have the same primary structure as human insulin:
"Insulin glargine differs from human insulin in that the amino acid asparagine at position A21 is replaced by glycine and two arginines are added to the C-terminus of the B-chain."
Synthetic insulin is the pride and joy of the biotech industry, being the first successful product produced through recombinant DNA technology; a technology which would eventually take the world by storm through its use in developing most of the GM crops in our present-day Biotech/Big Chem owned agricultural model, and is now the basis for billions of dollars of products in the food, medical and chemical industries, with an untold vastitude of mostly unexplored health risks.
The new study enrolled 6,484 subjects with type 2 diabetes who were eventually given progressed insulin monotherapy from 2000 onwards and who were tracked for an average of 3.3 years.
The number of adverse events in the insulin treated group were reported as follows:
Major Cardiovascular Events [MACE]: 342
Cancer Diagnoses: 382.
The adjusted hazard ratios (a measurement of health risk) in relation to one unit increases in insulin dose were a 54% increased risk for all-cause mortality, 37% increased risk for Major Cardiovascular Events, and a 35% increased risk for cancer, clearly indicating that the insulin they were given were both cardiotoxic and carcinogenic.
The study concluded:
"There was an association between increasing exogenous insulin dose and increased risk of all-cause mortality, cancer and MACE [major adverse cardiovascular events] in people with type 2 diabetes."
GMO Insulin Accelerates the Demise of Type 2 Diabetics
As we reported recently in an article titled, "GMO Insulin Causes Type 1 Diabetes in Type 2 Diabetics, Study Finds," synthetic insulin produced through genetically modified organisms accelerates disease progression in type 2 diabetics, contributing to the condition known as 'double diabetes' which is the development of type 1 (insufficient endogenous insulin) following unsuccessful treatment of type 2 (inability to respond to insulin) diabetes. This is all the more tragic considering that research on turmeric extract, ginger, and the low-carbohydrate diet, to name but a few natural alternatives, shows that type 2 diabetes can be both treated and even reversed naturally. Additionally, type 1 diabetes, which is widely promoted as 'incurable' by the dominant medical establishment, may be reversible through the stimulation of the regeneration of the insulin-producing beta cells within the pancreas and/or removal of the root causes of damage to the insulin-producing cells. See our article: 10 Natural Substances That Could Help Cure Type 1 Diabetes
It All Depends on The Folding Pattern of Insulin (Conformation)
Probably the most fatal error in the field of molecular biology over the past half century is the hypothesis known as the central dogma (1956, Francis Crick) that all biologically/physiologically important information is located solely in the primary sequence of nucleic acid stored within the 3 billion base pairs that make up the DNA of our genome. According to this theory, when a complex protein like insulin is produced, RNA simply transcribes the information templated in the DNA to produce the structure of insulin: the insulin polypeptide (51 linearly attached amino acids), end of story.
But nothing could be further from the truth. In order for a protein to assume its native, functional state (e.g. the insulin molecule in its fully folded 3D configuration) it must move through a practically infinite number of potential three-dimensional forms that it could randomly fold into to reach its natural (native), perfect form. This remarkable fact is known as Levinthal's paradox.
How does insulin, or any complex folded protein, get the information (literally 'to put form into') to do so? We simply don't know. But what we do know is that it must come from the 'outside,' or 'above,' which is what the field of epigenetics is dedicated to understanding. Also, it means one can not construct from the 'bottom up,' as the pharmaceutical industry has attempted thus far, the thing itself.
In other words, we know that while genetically modified yeast or bacteria can produce a primary structure of 51 linearly connected amino acids similar to human insulin, it does not have the same secondary, tertiary and quaternary folding patterns and therefore can not perform the same functions in the body as the natural form. This could account for why insulin replacement and/or adjunct therapy, even though it may effectively lower blood sugar (the target determinant for drug efficacy), is still associated with increased morbidity and mortality.